Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Effects of Serotonin Transporter Inhibition on the Subjective Response to LSD in Healthy Subjects

To see complete record on, please visit this link

Id: NCT05175430

Organisation Name: University Hospital, Basel, Switzerland

Overal Status: Recruiting

Start Date: October 24, 2022

Last Update: October 26, 2022

Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary: Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression and anxiety. SSRIs like paroxetine are first-line treatments for depression and anxiety disorders. Paroxetine acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.

  • Healthy

Total execution time in seconds: 0.50207901000977